MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Low Back Pain

Phase 3
Not yet recruiting
Conditions
Chronic Low Back Pain
Interventions
Other: Placebo
First Posted Date
2025-05-02
Last Posted Date
2025-05-02
Lead Sponsor
Vertanical GmbH
Target Recruit Count
700
Registration Number
NCT06956014

Acute Effects of THC in Older Adult

Phase 1
Not yet recruiting
Conditions
Age-related Cognitive Decline
Interventions
Drug: Placebo
First Posted Date
2025-04-29
Last Posted Date
2025-04-29
Lead Sponsor
Yale University
Target Recruit Count
60
Registration Number
NCT06948136
Locations
🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

Cannabinoids for Osteoarthritis Pain Effectiveness Trial

Not Applicable
Not yet recruiting
Conditions
Osteoarthritis of Knee
Osteoarthritis Hip
Interventions
Drug: Placebo
First Posted Date
2025-03-17
Last Posted Date
2025-05-21
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
100
Registration Number
NCT06878417
Locations
🇨🇦

University Health Network, Toronto, Ontario, Canada

🇨🇦

Women's College Hospital, Toronto, Ontario, Canada

🇨🇦

McGill University Health Centre/Montreal General Hospital, Montreal, Quebec, Canada

High Potency Cannabis: Acute and Protracted Effects

Phase 1
Not yet recruiting
Conditions
Abuse Cannabis
Pain
Pharmacokinetics
Interventions
Drug: High dose THC
First Posted Date
2025-03-05
Last Posted Date
2025-03-05
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
30
Registration Number
NCT06859723

THC and CBD: a Controlled Human Study Probing a Harm Reduction Strategy

Phase 1
Not yet recruiting
Conditions
Abuse, Drug
Pain
Interventions
Drug: Placebo
Drug: CBD 20 mg
Drug: CBD 40 mg
Drug: CBD 80 mg
First Posted Date
2025-03-05
Last Posted Date
2025-03-05
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
30
Registration Number
NCT06859710

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

Phase 2
Not yet recruiting
Conditions
Endometriosis
Endometriosis Related Pain
Endometriosis, Pain
Interventions
First Posted Date
2025-02-19
Last Posted Date
2025-02-20
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
75
Registration Number
NCT06834997
Locations
🇺🇸

Baylor College of Medicine, Houston, Texas, United States

Investigation of Psychedelic Effects in Psychoactive Substances

Phase 1
Recruiting
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Drug: Placebo
Drug: Dextromethorphan (DXM)
Drug: Methylenedioxymethamphetamine (MDMA)
First Posted Date
2025-01-14
Last Posted Date
2025-02-06
Lead Sponsor
Johns Hopkins University
Target Recruit Count
50
Registration Number
NCT06772753
Locations
🇺🇸

Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States

Research Investigating Drug Effects-2 (RiDE-2)

Early Phase 1
Not yet recruiting
Conditions
Cannabis Use
Healthy
Substance Use Disorder (SUD)
Interventions
Drug: Placebo Oral Capsule
First Posted Date
2025-01-06
Last Posted Date
2025-01-06
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
144
Registration Number
NCT06758596
Locations
🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Phase 2
Not yet recruiting
Conditions
Breast Carcinoma
Chemotherapy-Induced Peripheral Neuropathy
Colon Carcinoma
Interventions
Procedure: Biospecimen Collection
Other: Survey Administration
Drug: Placebo Administration
First Posted Date
2024-12-13
Last Posted Date
2024-12-13
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
120
Registration Number
NCT06731894
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

City of Hope at Irvine Lennar, Irvine, California, United States

Pilot fMRI Studies of Aging-Related Effects of THC

Phase 2
Not yet recruiting
Conditions
THC
Interventions
Drug: Placebo
First Posted Date
2024-10-17
Last Posted Date
2025-03-28
Lead Sponsor
Yale University
Target Recruit Count
10
Registration Number
NCT06647524
Locations
🇺🇸

Olin Neuropsychiatric Research Center at Hartford Healthcare, Hartford, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath